Our top pick for
bluebird bio, Inc is a biotechnology business based in the US. bluebird bio shares (BLUE) are listed on the NASDAQ and all prices are listed in US Dollars. bluebird bio employs 1,171 staff and has a trailing 12-month revenue of around USD$250 million.
|52-week range||USD$24.24 - USD$75.995|
|50-day moving average||USD$44.3912|
|200-day moving average||USD$50.1733|
|Wall St. target price||USD$50.53|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-12.004|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
bluebird bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into bluebird bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$250 million|
|Gross profit TTM||USD$-540,717,000|
|Return on assets TTM||-21.29%|
|Return on equity TTM||-42.89%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 5.9 million bluebird bio shares held short by investors – that's known as bluebird bio's "short interest". This figure is 3.2% down from 6.1 million last month.
There are a few different ways that this level of interest in shorting bluebird bio shares can be evaluated.
bluebird bio's "short interest ratio" (SIR) is the quantity of bluebird bio shares currently shorted divided by the average quantity of bluebird bio shares traded daily (recently around 1.3 million). bluebird bio's SIR currently stands at 4.7. In other words for every 100,000 bluebird bio shares traded daily on the market, roughly 4700 shares are currently held short.
However bluebird bio's short interest can also be evaluated against the total number of bluebird bio shares, or, against the total number of tradable bluebird bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case bluebird bio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 bluebird bio shares in existence, roughly 90 shares are currently held short) or 0.1303% of the tradable shares (for every 100,000 tradable bluebird bio shares, roughly 130 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against bluebird bio.
Find out more about how you can short bluebird bio stock.
We're not expecting bluebird bio to pay a dividend over the next 12 months.
Over the last 12 months, bluebird bio's shares have ranged in value from as little as $24.24 up to $75.995. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while bluebird bio's is 1.7487. This would suggest that bluebird bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.